Companies ›Consumer Cyclicals ›LOVE.TO

LOVE.TO — Toronto Stock Exchange Home Furnishings

Cannara Biotech Inc.

C$1,67

Open in Charts → Attach watcher ⌖

— —

CAD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

20,7 %

ROE

12,8 %

Net margin

12,2 %

Debt / equity

0,41

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

2026-08-28

Ex-dividend

—

TR 1Y

—

About

LOVE.TO operates in the healthcare sector, primarily engaged in the pharmaceuticals industry, and generates revenue through the provision of healthcare facilities and services.

Business. LOVE.TO is a healthcare company operating within the Healthcare Facilities & Services industry, with primary activities in pharmaceuticals. The firm generates revenue through service-based models and is listed on the Toronto Stock Exchange under the ticker LOVE.TO. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.

Classification99 %

SectorConsumer Discretionary

Industry groupHome Furnishings

Generated · model-assisted

Sell-side consensus

BUY4 analysts

4 buy0 hold0 sell

Avg 12m price target2,97

Analyst recommendations

4 analysts · consensus Buy

Buy4

Hold0

Sell0

12-month price target

2,97

Consensus of sell-side coverage.

Upcoming events

EarningsQ2 2026 earnings (expected)2026-08-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

4 analysts · indicative

Ownership→

Morgan Stanley Smith Barney LLC

largest disclosed fund holder

Profitability→

12,8 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning LOVE.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary · THIS SECTOR+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to LOVE.TO. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ2 2026 earnings (expected)2026-08-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

LOVE.TO is a healthcare company operating within the Healthcare Facilities & Services industry, with primary activities in pharmaceuticals. The firm generates revenue through service-based models and is listed on the Toronto Stock Exchange under the ticker LOVE.TO. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.

Classification99 %

SectorConsumer Discretionary

Industry groupHome Furnishings

AI synthesis

GENERATED

LOVE.TO maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.41, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 2.4, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk if not managed effectively.

In terms of profitability, LOVE.TO demonstrates a return on equity (ROE) of 12.79% and a return on assets (ROA) of 7.75%, which are key metrics for assessing the efficiency of capital use and asset management. These figures suggest that the company is generating reasonable returns relative to its equity and asset base. However, a direct comparison to industry medians is necessary to fully evaluate its performance against peers.

The company's revenue is primarily concentrated in the pharmaceuticals segment, with no significant geographic diversification disclosed. This concentration may expose the company to specific market risks, such as regulatory changes or shifts in consumer demand within the pharmaceuticals industry. The lack of geographic diversification could also limit growth opportunities in other regions.

LOVE.TO's growth trajectory is influenced by its current financial performance and future outlook. The company's operating cash flow of 20,013,430 CAD and free cash flow of 14,874,440 CAD indicate a positive cash generation capability, which supports reinvestment and potential expansion. Analysts have provided a mean price target of 2.97 CAD and a median price target of 3.00 CAD, reflecting a generally positive outlook for the stock. The mean recommendation of 1.75 suggests a slight bias towards a buy rating, with one strong buy and three buy recommendations.

The risk assessment for LOVE.TO highlights a medium liquidity risk and a low dilution risk. The company's net cash position being negative after subtracting total debt is a key flag that could impact its liquidity. Additionally, the company has not shown any dilution potential in the basic shares outstanding, indicating a stable equity structure. However, the company's reliance on debt financing and the potential for negative net cash could affect its financial stability.

Recent events and filings for LOVE.TO include analyst estimates and price targets, which provide insights into market sentiment. The company has not disclosed any significant recent events or transcripts that would indicate major operational or strategic changes. The analyst estimates suggest a generally positive outlook, with a range of price targets and a mean recommendation that leans towards a buy.

Key takeaways

LOVE.TO has a balanced capital structure with a debt-to-equity ratio of 0.41.
The company's return on equity (12.79%) and return on assets (7.75%) indicate efficient capital and asset use.
LOVE.TO's revenue is primarily concentrated in the pharmaceuticals segment, with no significant geographic diversification.
Analysts have provided a generally positive outlook, with a mean price target of 2.97 CAD and a median price target of 3.00 CAD.
The company faces a medium liquidity risk due to a negative net cash position after subtracting total debt.
**margin_outlook_rationale**: The company's gross profit margin is expected to remain stable, supported by consistent revenue and cost management.
**rd_outlook_rationale**: Research and development expenditures are not disclosed, but the company's focus on pharmaceuticals suggests ongoing investment in innovation.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

C$1,67

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

C$102.2M

Net cashⓘ

-C$41.6M

Current ratioⓘ

2.4

Debt / equityⓘ

0.4

ROAⓘ

7.8%

ROEⓘ

12.8%

Cash conversionⓘ

153.0%

CapEx / revenueⓘ

-4.6%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures

Partners2

Best Buy Co IncBBY.OPartner95%Source ↗

COSTCO WHOLESALE CORPORATIONCOST.OPartner95%Source ↗

Supply chain

Vendors → LOVE ↔ Partners → Customers · click any node to drill

2 mentions in 10-K0 from corporate websites0 from news dispatches

Updated 2026-06-24

Peer comparison

Peer comparison7 peers · vs LOVE · multiples and returns

MHK—

Mohawk Industries Inc

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

SGI—

Somnigroup International Inc

$66,64

13,9B USD

P/E

30,1x

-27,4 vs self

Div yield

0,8 %

— vs self

ROE

16,8 %

+14,9 vs self

SNBR—

Sleep Number Corp

$0,07

1,7M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

22,8 %

+20,9 vs self

PRPL—

Purple Innovation Inc

$8,90

970,0M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

173,2 %

+171,3 vs self

NTZ—

NTZ

$1,29

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BSET—

Bassett Furniture Inds

$19,57

169,2M USD

P/E

20,2x

-37,4 vs self

Div yield

5,6 %

— vs self

ROE

3,7 %

+1,8 vs self

HOFT—

Hooker Furnishings Corp

$14,20

153,0M USD

P/E

—

— vs self

Div yield

3,5 %

— vs self

ROE

-1,9 %

-3,7 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

0,12

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-10 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	0,12
Revenue	—no estimate	—no estimate	122,8M CAD
Operating income	—no estimate	—no estimate	19,0M CAD

Full-year consensus mean (period as reported by source) · consensus in CAD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution4 analysts

Strong buy1

Buy3

Hold0

Sell0

Strong sell0

12-month price targetC$2,97 · Median C$3,00

Low C$2,37High C$3,50

Operating income · consensus19,0M CAD

EPS surprise

+19,1 %

reported vs consensus · beat

Revenue surprise

−12,6 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

LowC$2,37

MeanC$2,97

MedianC$3,00

HighC$3,50

SpotC$1,67

+77.7 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin20,7 %Best in class

Net Margin12,2 %Best in class

ROE12,8 %Best in class

Capex / Rev-4,6 %Below median

D/E0,41Below median

Cash Conv1,53Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 281 729 sh23 exercises · 17 grants11 insiders

Farag AndrewEVP and CFO · Restricted Stock Units → Common StockAcquired 28 843grant · 2026-06-23
Siegner Keith R.EVP and CFO · Restricted Stock Units → Common StockDisposed 5 071exercise · 2026-06-11
Nelson Shawn DavidDirector, Chief Executive Officer · Restricted Stock Units → Common StockDisposed 9 616exercise · 2026-06-11
Fox MaryPresident · Restricted Stock Units → Common StockDisposed 9 616exercise · 2026-06-11
Romig ShirleyDirector · Restricted Stock Units → Common StockDisposed 6 308exercise · 2026-06-10
McLallen Walter FieldDirector · Restricted Stock Units → Common StockDisposed 6 308exercise · 2026-06-10
Leite Sharon MDirector · Restricted Stock Units → Common StockDisposed 6 308exercise · 2026-06-10
HEYER ANDREW RDirector · Restricted Stock Units → Common StockDisposed 6 308exercise · 2026-06-10
Mehra VineetDirector · Restricted Stock Units → Common StockDisposed 6 308exercise · 2026-06-10
Leite Sharon MDirector · Restricted Stock Units → Common StockAcquired 7 947grant · 2026-06-09
HEYER ANDREW RDirector · Restricted Stock Units → Common StockAcquired 7 947grant · 2026-06-09
Martello Wan LingDirector · Restricted Stock Units → Common StockAcquired 7 947grant · 2026-06-09
Martello Wan LingDirector · Restricted Stock Units → Common StockAcquired 4 768grant · 2026-06-09
Romig ShirleyDirector · Restricted Stock Units → Common StockAcquired 7 947grant · 2026-06-09
Boehme AlanDirector · Restricted Stock Units → Common StockAcquired 7 947grant · 2026-06-09
Mehra VineetDirector · Restricted Stock Units → Common StockAcquired 7 947grant · 2026-06-09
McLallen Walter FieldDirector · Restricted Stock Units → Common StockAcquired 7 947grant · 2026-06-09
Siegner Keith R.EVP and CFO · Restricted Stock Units → Common StockAcquired 34 966grant · 2026-04-15
Siegner Keith R.EVP and CFO · Restricted Stock Units → Common StockDisposed 7 714exercise · 2026-04-15
Nelson Shawn DavidDirector, Chief Executive Officer · Restricted Stock Units → Common StockAcquired 77 701grant · 2026-04-15
Nelson Shawn DavidDirector, Chief Executive Officer · Restricted Stock Units (Performance-based Vesting) → Common StockAcquired 77 701grant · 2026-04-15
Nelson Shawn DavidDirector, Chief Executive Officer · Restricted Stock Units → Common StockDisposed 4 848exercise · 2026-04-15
Nelson Shawn DavidDirector, Chief Executive Officer · Restricted Stock Units → Common StockDisposed 17 066exercise · 2026-04-15
Siegner Keith R.EVP and CFO · Restricted Stock Units (Performance-based Vesting) → Common StockAcquired 34 966grant · 2026-04-15
Fox MaryPresident · Restricted Stock Units → Common StockDisposed 17 066exercise · 2026-04-15

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

LOVE.TO Market data — financials · 2026-05-28
Cannara Biotech Inc Market data — analyst estimates · 2026-05-28

Ownership & reference

Top holders

Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M

Leadership

Zohar KrivorotChairman of the Board, Chief Executive Officer

Insider activity

Net buying4 buys · 0 sellsnet $515K8 insiders · last 365d

Fox MaryPresident · Common Stock, $0.00001 par valueBought 1 720 @ $14,41$25K · 2026-06-22
Nelson Shawn DavidDirector, Chief Executive Officer · Common Stock, $0.00001 par valueBought 1 830 @ $13,64$25K · 2026-06-22
HEYER ANDREW RDirector · Common Stock, par value $0.00001Bought 30 000 @ $14,68$440K · 2026-06-18
Fox MaryPresident · Common Stock, $0.00001 par valueOther 4 311 @ $16,30$70K · 2026-06-11
Siegner Keith R.EVP and CFO · Common Stock, $0.00001 par valueOther 5 071 · 2026-06-11
Siegner Keith R.EVP and CFO · Common Stock, $0.00001 par valueOther 2 350 @ $16,30$38K · 2026-06-11
Siegner Keith R.EVP and CFO · Common Stock, $0.00001 par valueOther 2 226 @ $16,30$36K · 2026-06-11
Nelson Shawn DavidDirector, Chief Executive Officer · Common Stock, $0.00001 par valueOther 9 616 · 2026-06-11
Nelson Shawn DavidDirector, Chief Executive Officer · Common Stock, $0.00001 par valueOther 4 357 @ $16,30$71K · 2026-06-11
Nelson Shawn DavidDirector, Chief Executive Officer · Common Stock, $0.00001 par valueOther 4 126 @ $16,30$67K · 2026-06-11
Fox MaryPresident · Common Stock, $0.00001 par valueOther 9 616 · 2026-06-11
Fox MaryPresident · Common Stock, $0.00001 par valueOther 4 553 @ $16,30$74K · 2026-06-11
Leite Sharon MDirector · Common Stock, par value $0.00001Other 6 308 · 2026-06-10
Mehra VineetDirector · Common Stock, par value $0.00001Other 6 308 · 2026-06-10
McLallen Walter FieldDirector · Common Stock, $0.00001 par valueOther 6 308 · 2026-06-10
HEYER ANDREW RDirector · Common Stock, par value $0.00001Other 6 308 · 2026-06-10
Romig ShirleyDirector · Common Stock, $0.00001 par valueOther 6 308 · 2026-06-10
Nelson Shawn DavidDirector, Chief Executive Officer · Common Stock, $0.00001 par valueBought 1 477 @ $16,95$25K · 2026-04-16
Nelson Shawn DavidDirector, Chief Executive Officer · Common Stock, $0.00001 par valueOther 17 066 · 2026-04-15
Nelson Shawn DavidDirector, Chief Executive Officer · Common Stock, $0.00001 par valueOther 7 731 @ $16,65$129K · 2026-04-15
Nelson Shawn DavidDirector, Chief Executive Officer · Common Stock, $0.00001 par valueOther 2 040 @ $16,65$34K · 2026-04-15
Nelson Shawn DavidDirector, Chief Executive Officer · Common Stock, $0.00001 par valueOther 7 113 @ $16,65$118K · 2026-04-15
Fox MaryPresident · Common Stock, $0.00001 par valueOther 4 848 · 2026-04-15
Fox MaryPresident · Common Stock, $0.00001 par valueOther 2 296 @ $16,65$38K · 2026-04-15
Fox MaryPresident · Common Stock, $0.00001 par valueOther 17 066 · 2026-04-15

Short positioning

3.2Mshares short-2.4% vs prior

15.09days to cover

21.1%short of daily vol

7.0Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

LOVE.TOCanonical

Toronto Stock Exchange · CAD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Relationship graph

This companySectorPartners

Evidence & claims

From filings & derived data

Cash & equivalents (YoY) (2026-02-01 vs 2025-02-02): 21.6%Derived (calculated)
R&D expense (YoY) (2026-02-01 vs 2025-02-02): -16.7%Derived (calculated)
Total liabilities (YoY) (2026-02-01 vs 2025-02-02): 0.0%Derived (calculated)
Total assets (YoY) (2026-02-01 vs 2025-02-02): 0.5%Derived (calculated)
Shareholders' equity (YoY) (2026-02-01 vs 2025-02-02): 1.1%Derived (calculated)
Revenue (YoY) (2026-02-01 vs 2025-02-02): 2.4%Derived (calculated)
EPS (diluted) (YoY) (2026-02-01 vs 2025-02-02): -59.4%Derived (calculated)
EPS (basic) (YoY) (2026-02-01 vs 2025-02-02): -62.7%Derived (calculated)
Gross profit (YoY) (2026-02-01 vs 2025-02-02): -1.2%Derived (calculated)
Net margin (FY 2026-02-01): 0.6%Derived (calculated)
Gross margin (FY 2026-02-01): 56.4%Derived (calculated)
Return on equity (FY 2026-02-01): 1.9%Derived (calculated)
Return on assets (FY 2026-02-01): 0.8%Derived (calculated)
Current ratio (FY 2026-02-01): 1.61xDerived (calculated)
Debt-to-equity (FY 2026-02-01): 1.44xDerived (calculated)
Operating income (YoY) (2026-02-01 vs 2025-02-02): -60.7%Derived (calculated)
Cost of revenue (YoY) (2026-02-01 vs 2025-02-02): 7.5%Derived (calculated)
Capex (YoY) (2026-02-01 vs 2025-02-02): 10.0%Derived (calculated)
Net income (YoY) (2026-02-01 vs 2025-02-02): -64.7%Derived (calculated)
Operating cash flow (YoY) (2026-02-01 vs 2025-02-02): 26.6%Derived (calculated)
EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing
Total operating expenses (annual): USD 387.85MSEC XBRL filing
Net income (annual): USD 4.1MSEC XBRL filing
Gross profit (annual): USD 393.21MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-08-28EVENTUpcomingQ2 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-23 00:00 UTCINSIDER34 insider transactions — 2026-06 · net buy $133k 17 derivative

2026-06-23INSIDERFarag Andrew acquired 28.8k sh Restricted Stock Units — EVP and CFO

2026-06-22INSIDERFox Mary bought 1.7k sh Common Stock, $0.00001 par value — President ~$25k

2026-06-22INSIDERNelson Shawn David bought 1.8k sh Common Stock, $0.00001 par value — Director, Chief Executive Officer ~$25k

2026-06-18INSIDERHEYER ANDREW R bought 30.0k sh Common Stock, par value $0.00001 — Director ~$440k

2026-06-15FILINGCURRENT REPORT →

2026-06-11FILING10-Q filing →

2026-06-11FILING8-K filing →

2026-06-11INSIDERFox Mary transacted 4.3k sh Common Stock, $0.00001 par value — President ~$70k

2026-06-11INSIDERSiegner Keith R. transacted 5.1k sh Common Stock, $0.00001 par value — EVP and CFO

2026-06-11INSIDERSiegner Keith R. transacted 2.4k sh Common Stock, $0.00001 par value — EVP and CFO ~$38k

2026-06-11INSIDERSiegner Keith R. transacted 2.2k sh Common Stock, $0.00001 par value — EVP and CFO ~$36k

2026-06-11INSIDERNelson Shawn David transacted 9.6k sh Common Stock, $0.00001 par value — Director, Chief Executive Officer

2026-06-11INSIDERNelson Shawn David transacted 4.4k sh Common Stock, $0.00001 par value — Director, Chief Executive Officer ~$71k

2026-06-11INSIDERNelson Shawn David transacted 4.1k sh Common Stock, $0.00001 par value — Director, Chief Executive Officer ~$67k

2026-06-11INSIDERFox Mary transacted 9.6k sh Common Stock, $0.00001 par value — President

2026-06-11INSIDERFox Mary transacted 4.6k sh Common Stock, $0.00001 par value — President ~$74k

2026-06-11INSIDERNelson Shawn David disposed of 9.6k sh Restricted Stock Units — Director, Chief Executive Officer

2026-06-11INSIDERSiegner Keith R. disposed of 5.1k sh Restricted Stock Units — EVP and CFO

2026-06-11INSIDERFox Mary disposed of 9.6k sh Restricted Stock Units — President

2026-06-10INSIDERLeite Sharon M transacted 6.3k sh Common Stock, par value $0.00001 — Director

2026-06-10INSIDERMehra Vineet transacted 6.3k sh Common Stock, par value $0.00001 — Director

2026-06-10INSIDERMcLallen Walter Field transacted 6.3k sh Common Stock, $0.00001 par value — Director

2026-06-10INSIDERHEYER ANDREW R transacted 6.3k sh Common Stock, par value $0.00001 — Director

2026-06-10INSIDERRomig Shirley transacted 6.3k sh Common Stock, $0.00001 par value — Director

2026-06-10INSIDERMehra Vineet disposed of 6.3k sh Restricted Stock Units — Director

2026-06-10INSIDERHEYER ANDREW R disposed of 6.3k sh Restricted Stock Units — Director

2026-06-10INSIDERRomig Shirley disposed of 6.3k sh Restricted Stock Units — Director

2026-06-10INSIDERLeite Sharon M disposed of 6.3k sh Restricted Stock Units — Director

2026-06-10INSIDERMcLallen Walter Field disposed of 6.3k sh Restricted Stock Units — Director

2026-06-09FILING8-K filing →

2026-06-09INSIDERLeite Sharon M acquired 7.9k sh Restricted Stock Units — Director

2026-06-09INSIDERMcLallen Walter Field acquired 7.9k sh Restricted Stock Units — Director

2026-06-09INSIDERMehra Vineet acquired 7.9k sh Restricted Stock Units — Director

2026-06-09INSIDERBoehme Alan acquired 7.9k sh Restricted Stock Units — Director

2026-06-09INSIDERRomig Shirley acquired 7.9k sh Restricted Stock Units — Director

Showing the 40 most recent of 62 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread